Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Takeshima, Tappei, Miyoshi, Yasuhide, Nakaigawa, Noboru, Yao, Masahiro, Tanabe, Mikiko, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696783/
https://www.ncbi.nlm.nih.gov/pubmed/31427949
http://dx.doi.org/10.1159/000501716
_version_ 1783444325858803712
author Kawahara, Takashi
Takeshima, Tappei
Miyoshi, Yasuhide
Nakaigawa, Noboru
Yao, Masahiro
Tanabe, Mikiko
Uemura, Hiroji
author_facet Kawahara, Takashi
Takeshima, Tappei
Miyoshi, Yasuhide
Nakaigawa, Noboru
Yao, Masahiro
Tanabe, Mikiko
Uemura, Hiroji
author_sort Kawahara, Takashi
collection PubMed
description COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwent right nephrectomy in 2015. In 2017, iliac bone metastasis was found and consequently lung metastasis was developed. Pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers during pazopanib treatment for more than two years and the size and number of lung metastases decreased. We herein report a case of successful control of metastatic renal cell carcinoma for more than two years using pazopanib treatment.
format Online
Article
Text
id pubmed-6696783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-66967832019-08-19 Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib Kawahara, Takashi Takeshima, Tappei Miyoshi, Yasuhide Nakaigawa, Noboru Yao, Masahiro Tanabe, Mikiko Uemura, Hiroji Case Rep Oncol Case Report COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwent right nephrectomy in 2015. In 2017, iliac bone metastasis was found and consequently lung metastasis was developed. Pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers during pazopanib treatment for more than two years and the size and number of lung metastases decreased. We herein report a case of successful control of metastatic renal cell carcinoma for more than two years using pazopanib treatment. S. Karger AG 2019-07-16 /pmc/articles/PMC6696783/ /pubmed/31427949 http://dx.doi.org/10.1159/000501716 Text en Copyright © 2019 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kawahara, Takashi
Takeshima, Tappei
Miyoshi, Yasuhide
Nakaigawa, Noboru
Yao, Masahiro
Tanabe, Mikiko
Uemura, Hiroji
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title_full Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title_fullStr Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title_full_unstemmed Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title_short Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
title_sort long-term control of metastatic renal cell carcinoma using pazopanib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696783/
https://www.ncbi.nlm.nih.gov/pubmed/31427949
http://dx.doi.org/10.1159/000501716
work_keys_str_mv AT kawaharatakashi longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT takeshimatappei longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT miyoshiyasuhide longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT nakaigawanoboru longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT yaomasahiro longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT tanabemikiko longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib
AT uemurahiroji longtermcontrolofmetastaticrenalcellcarcinomausingpazopanib

Ejemplares similares